Emergent Biosolutions (EBS) Tops Q2 EPS by 6c, Posts FY11 Guidance
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $4.50 -1.96%
Financial Fact:
Interest expense: -2.05M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Interest expense: -2.05M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Emergent Biosolutions (NYSE: EBS) reported Q2 EPS of $0.40, $0.06 better than the analyst estimate of $0.34. Revenue for the quarter came in at $88.1 million versus the consensus estimate of $84.2 million.
Emergent Biosolutions sees FY2011 net income of $15 to $25 million. Emergent Biosolutions sees FY2011 revenue of $270-$290 million, versus the consensus of $326.68 million.
Emergent Biosolutions sees FY2011 net income of $15 to $25 million. Emergent Biosolutions sees FY2011 revenue of $270-$290 million, versus the consensus of $326.68 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c
- Motorsport Games Inc. (MSGM) Tops Q2 EPS by 33c
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
